MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/ibd/izac158

Медицинская библиотека · Inflammatory bowel diseases · 2023

Early Initiation of Antitumor Necrosis Factor Therapy Reduces Postoperative Recurrence of Crohn's Disease Following Ileocecal Resection.

Axelrad Jordan E, Li Terry, Bachour Salam P, Nakamura Takahiro I, Shah Ravi, Sachs Michael C, Chang Shannon, Hudesman David P, Holubar Stefan D, Lightner Amy L, Barnes Edward L, Cohen Benjamin L, Rieder Florian, Esen Eren, Remzi Feza, Regueiro Miguel, Click Benjamin

СтатьяПоддержка NIH: внешняя программаПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

BACKGROUND

Postoperative recurrence (POR) of Crohn's disease (CD) is common after surgical resection. We aimed to compare biologic type and timing for preventing POR in adult CD patients after ileocecal resection (ICR).

METHODS

We performed a retrospective cohort study of CD patients who underwent an ICR at 2 medical centers. Recurrence was defined by endoscopy (≥ i2b Rutgeerts score) or radiography (active inflammation in neoterminal ileum) and stratified by type and timing of postoperative prophylactic biologic within 12 weeks following an ICR (none, tumor necrosis factor antagonists [anti-TNF], vedolizumab, and ustekinumab).

RESULTS

We identified 1037 patients with CD who underwent an ICR. Of 278 (26%) who received postoperative prophylaxis, 80% were placed on an anti-TNF agent (n = 223) followed by ustekinumab (n = 28, 10%) and vedolizumab (n = 27, 10%). Prophylaxis was initiated in 35% within 4 weeks following an ICR and in 65% within 4 to 12 weeks. After adjusting for factors associated with POR, compared with no biologic prophylaxis, the initiation of an anti-TNF agent within 4 weeks following an ICR was associated with a reduction in POR (adjusted hazard ratio, 0.61; 95% CI, 0.40-0.93). Prophylaxis after 4 weeks following an ICR or with vedolizumab or ustekinumab was not associated with a reduction in POR compared with those who did not receive prophylaxis.

CONCLUSION

Early initiation of an anti-TNF agent within 4 weeks following an ICR was associated with a reduction in POR. Vedolizumab or ustekinumab, at any time following surgery, was not associated with a reduction in POR, although sample size was limited.

Для цитирования: Axelrad Jordan E, Li Terry, Bachour Salam P, Nakamura Takahiro I, Shah Ravi, Sachs Michael C, Chang Shannon, Hudesman David P, Holubar Stefan D, Lightner Amy L, Barnes Edward L, Cohen Benjamin L, Rieder Florian, Esen Eren, Remzi Feza, Regueiro Miguel, Click Benjamin. Early Initiation of Antitumor Necrosis Factor Therapy Reduces Postoperative Recurrence of Crohn's Disease Following Ileocecal Resection.. Inflammatory bowel diseases. 2023. DOI: 10.1093/ibd/izac158.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.